NASDAQ · Key Statistics

Galectin Therapeutics Inc. (GALT) P/E Ratio, ROE & Key Statistics

$2.91 NASDAQ: GALT Market Cap $191.64M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Galectin Therapeutics Inc. (GALT), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-8.96
P/B ratioShare price divided by book value per share.-7.70
P/S ratioMarket value divided by annual revenue.0.00
PEG ratioP/E divided by the earnings growth rate.-0.18
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.-29.84
EV / RevenueEnterprise value against annual revenue.0.00
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-11.16%
Free cash flow yieldFree cash flow as a percentage of market value.-7.35%
Price / free cash flowMarket value divided by free cash flow.-13.61

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.0.00%
Operating marginRevenue left after operating costs.0.00%
Net marginRevenue left after every cost, including tax and interest.0.00%
Return on equityProfit as a percentage of shareholders’ equity.21.65%
Return on assetsProfit as a percentage of total assets.-178.26%
Return on capital employedOperating profit against the capital the business uses.34.21%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.0.28
Quick ratioThe same, excluding inventory.0.28
Cash ratioCash alone against current liabilities.2.25
Debt to equityTotal borrowings against shareholders’ equity.-0.95
Debt to assetsTotal borrowings against total assets.6.70
Interest coverageHow many times operating profit covers the interest bill.-2.22

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$0.48
Book value per shareShareholders’ equity divided by shares outstanding.−$0.37
Market capitalisationShare price times shares outstanding.$191.64M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$219.89M
EmployeesReported headcount.15

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Galectin Therapeutics Inc. (GALT) statistics — frequently asked questions

What is Galectin Therapeutics Inc.'s P/E ratio?

Galectin Therapeutics Inc. (GALT) trades on a price-to-earnings ratio of -8.96. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Galectin Therapeutics Inc.'s return on equity?

Galectin Therapeutics Inc. (GALT) reports a return on equity of 21.65%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Galectin Therapeutics Inc. carry?

Galectin Therapeutics Inc. (GALT) has a debt-to-equity ratio of -0.95, which compares total borrowings with shareholders' equity.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.